FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of ...
-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services ...
Lab is located in same building as PPD ® Laboratories’ Central Lab and will support Asia-Pacific oncology trials FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial ...
Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. NeoGenomics met analysts’ revenue expectations last quarter, ...
Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...
FORT MYERS, Fla., December 30, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results